Literature DB >> 19183105

Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment.

Christer Tannergren1, Anna Bergendal, Hans Lennernäs, Bertil Abrahamsson.   

Abstract

The purpose of this study was to increase the understanding of in vivo colonic drug absorption in humans by summarizing and evaluating all regional in vivo human absorption data with focus on the interpretation of the colonic absorption data in relation to intestinal permeability and solubility. In addition, the usefulness of the Biopharmaceutics Classification System (BCS) in early assessment of the in vivo colonic absorption potential of controlled release drug candidates was investigated. Clinical regional absorption data (Cmax, Tmax, and AUC) of 42 drugs were collected from journal articles, abstracts, and internal reports, and the relative bioavailability in the colon (Frel(colon)) was obtained directly or calculated. Bioavailability, fraction dose absorbed, and information if the compounds were substrates for P-glycoprotein (P-gp) or cytochrome P450 3A (CYP3A) were also obtained. The BCS I drugs were well absorbed in the colon (Frel(colon) > 70%), although some drugs had lower values due to bacterial degradation in the colon. The low permeability drugs (BCS III/IV) had a lower degree of absorption in the colon (Frel(colon) < 50%). There was a clear correlation between in vitro Caco-2 permeability and Frel(colon), and atenolol and metoprolol may function as permeability markers for low and high colonic absorption, respectively. No obvious effect of P-gp on the colonic absorption of the drugs in this study was detected. There was insufficient data available to fully assess the impact of low solubility and slow dissolution rate. The estimated in vivo fractions dissolved of the only two compounds administered to the colon as both a solution and as solid particles were 55% and 92%, respectively. In conclusion, permeability and solubility are important barriers to colonic absorption in humans, and in vitro testing of these properties is recommended in early assessment of colonic absorption potential.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19183105     DOI: 10.1021/mp800261a

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  19 in total

Review 1.  Coexistence of passive and carrier-mediated processes in drug transport.

Authors:  Kiyohiko Sugano; Manfred Kansy; Per Artursson; Alex Avdeef; Stefanie Bendels; Li Di; Gerhard F Ecker; Bernard Faller; Holger Fischer; Grégori Gerebtzoff; Hans Lennernaes; Frank Senner
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

Review 2.  Biomagnetic methods: technologies applied to pharmaceutical research.

Authors:  Luciana A Corá; Madileine F Américo; Ricardo B Oliveira; Cristina H R Serra; Oswaldo Baffa; Raul C Evangelista; Giselle F Oliveira; José Ricardo Aruda Miranda
Journal:  Pharm Res       Date:  2010-10-15       Impact factor: 4.200

3.  Physiologically Based Absorption Modeling to Design Extended-Release Clinical Products for an Ester Prodrug.

Authors:  Xuan Ding; Jeffrey S Day; David C Sperry
Journal:  AAPS J       Date:  2016-07-12       Impact factor: 4.009

4.  The fraction dose absorbed, in humans, and high jejunal human permeability relationship.

Authors:  Arik Dahan; Hans Lennernäs; Gordon L Amidon
Journal:  Mol Pharm       Date:  2012-05-04       Impact factor: 4.939

5.  A Monolayer of Primary Colonic Epithelium Generated on a Scaffold with a Gradient of Stiffness for Drug Transport Studies.

Authors:  Dulan B Gunasekara; Jennifer Speer; Yuli Wang; Daniel L Nguyen; Mark I Reed; Nicole M Smiddy; Joel S Parker; John K Fallon; Philip C Smith; Christopher E Sims; Scott T Magness; Nancy L Allbritton
Journal:  Anal Chem       Date:  2018-10-30       Impact factor: 6.986

Review 6.  Population-based mechanistic prediction of oral drug absorption.

Authors:  Masoud Jamei; David Turner; Jiansong Yang; Sibylle Neuhoff; Sebastian Polak; Amin Rostami-Hodjegan; Geoffrey Tucker
Journal:  AAPS J       Date:  2009-04-21       Impact factor: 4.009

7.  Function and expression of the proton-coupled amino acid transporter PAT1 along the rat gastrointestinal tract: implications for intestinal absorption of gaboxadol.

Authors:  M l Broberg; R Holm; H Tønsberg; S Frølund; K B Ewon; A l Nielsen; B Brodin; A Jensen; M A Kall; K V Christensen; C U Nielsen
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

8.  Translating Human Effective Jejunal Intestinal Permeability to Surface-Dependent Intrinsic Permeability: a Pragmatic Method for a More Mechanistic Prediction of Regional Oral Drug Absorption.

Authors:  Andrés Olivares-Morales; Hans Lennernäs; Leon Aarons; Amin Rostami-Hodjegan
Journal:  AAPS J       Date:  2015-05-19       Impact factor: 4.009

9.  Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS® Formulation of Oxybutynin.

Authors:  Andrés Olivares-Morales; Avijit Ghosh; Leon Aarons; Amin Rostami-Hodjegan
Journal:  AAPS J       Date:  2016-09-08       Impact factor: 4.009

10.  Model-based evaluation of the impact of formulation and food intake on the complex oral absorption of mavoglurant in healthy subjects.

Authors:  Thierry Wendling; Kayode Ogungbenro; Etienne Pigeolet; Swati Dumitras; Ralph Woessner; Leon Aarons
Journal:  Pharm Res       Date:  2014-11-26       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.